PubMed Health⌕ Search

Biomedical subjects

Karen O'Brien

Publications and source records attributed to Karen O'Brien.

6 recordsLinked to original sources
PubMed2006

Questioning complacency: climate change impacts, vulnerability, and adaptation in Norway.

Most European assessments of climate change impacts have been carried out on sectors and ecosystems, providing a narrow understanding of what climate change really means for society. Furthermore, the main focus has been on technological adaptations, with less attention paid to the process of climate change adaptation. In this article, we present and analyze findings from recent studies on climate change impacts, vulnerability, and adaptation in Norway, with the aim of identifying the wider social impacts of climate change. Three main lessons can be drawn. First, the potential thresholds and indirect effects may be more important than the direct, sectoral effects. Second, highly sensitive sectors, regions, and communities combine with differential social vulnerability to create both winners and losers. Third, high national levels of adaptive capacity mask the barriers and constraints to adaptation, particularly among those who are most vulnerable to climate change. Based on these results, we question complacency in Norway and other European countries regarding climate change impacts and adaptation. We argue that greater attention needs to be placed on the social context of climate change impacts and on the processes shaping vulnerability and adaptation.

Climate↗
PubMed2003

Testing for gestational diabetes.

In 1996, the American Diabetes Association reported that 12% of total health care expenditure in the United States was spent on diabetes and its complications. Screening for and treating gestational diabetes results in improved perinatal morbidity and mortality. Moreover, detecting gestational diabetes identifies women who are at risk of future type 2 diabetes. This article reviews several approaches to diagnosing gestational diabetes.

Adult↗
PubMed2002

Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: follow up study.

OBJECTIVE: To determine effects of five years of treatment with an oral continuous combined regimen of 2 mg 17beta-oestradiol and 1 mg norethisterone acetate on endometrial histology in postmenopausal women. DESIGN: Follow up study in postmenopausal women. SETTING: 31 menopause clinics in the United Kingdom. PARTICIPANTS: 534 postmenopausal women, all with an intact uterus, who had completed nine months of treatment with oral continuous combined 2 mg 17beta-oestradiol and 1 mg norethisterone acetate agreed to take part in a long term follow up study. Women were assigned to different groups on the basis of the treatment status immediately before entering the original study: 360 women had taken sequential oestrogen-progestogen hormone replacement therapy, 164 had taken no hormone replacement therapy, and 10 had taken unopposed oestrogen therapy. METHODS: Endometrial aspiration specimens were taken before the women started the continuous combined regimen, after 9 and 24-36 months, and at the end of the five year treatment period or on withdrawal from the study. MAIN OUTCOME MEASURE: Results of endometrial histology. RESULTS: The duration of treatment with continuous combined hormone replacement therapy was 4.4 (range 1.1-5.9) years. Data on endometrial specimens were available for 526 women after nine months of treatment, 465 women after 24-36 months of treatment, and 398 women who completed the five years treatment (345 women) or were withdrawn between the two latter visits for biopsies (53 women). No cases of endometrial hyperplasia or malignancy were detected at biopsy; 69% of women had an endometrium classified as atrophic or unassessable on completion of the study or withdrawal from it. Before the continuous combined therapy was started, complex hyperplasia was detected in 21 women who had taken sequential hormone replacement therapy before the study and in one who had taken unopposed oestrogen. All of these women had normal results on histological examination of endometrial tissue after nine months of treatment with continuous combined hormone replacement therapy, and hyperplasia did not recur after up to five years of treatment. CONCLUSIONS: Long term treatment (for up to five years) with continuous combined hormone replacement therapy containing oestradiol 2 mg and norethisterone 1 mg daily was associated with neither endometrial hyperplasia nor malignancy. In women who had complex hyperplasia during previous sequential or unopposed regimens, the endometrium returned to normal during treatment with continuous combined hormone replacement therapy. These findings provide reassurance about the long term safety of this continuous combined regimen in terms of the endometrium.

Administration, Oral↗
PubMed2002

Postpartum X-ray pelvimetry. Its use in calculating the fetal-pelvic index and predicting fetal-pelvic disproportion.

OBJECTIVE: To determine whether postpartum x-ray pelvimetry can be used to calculate the fetal-pelvic index (FPI) in future pregnancies. STUDY DESIGN: In stage I of the study, 10 gravid women, after 36 completed weeks' gestation, underwent x-ray pelvimetry before delivery. Pelvimetry was repeated within two days after delivery. Comparisons between antepartum and postpartum measurements were made using paired t tests and correlation coefficients. In stage II, 25 gravid women, after 36 completed weeks' gestation, underwent fetal ultrasound for biometry. X-ray pelvimetry was performed within two days after delivery. FPI was calculated for each pregnancy using antepartum fetal ultrasound and postpartum pelvimetry measurements. FPI calculations were correlated with the incidence of fetal-pelvic disproportion (FPD), as indicated by the requirement for cesarean section for arrest of active labor. Sensitivity, specificity and predictive value of FPI were assessed. RESULTS: In stage I, mean anteroposterior and transverse diameters of the pelvic inlet, midpelvis and pelvic outlet did not differ significantly. In stage II, the sensitivity of FPI for detecting FPD was 100%, specificity 95%, positive predictive value 80%, and negative predictive value 100%. CONCLUSION: Postpartum pelvimetry has the same association with FPD as antepartum pelvimetry. The strategy of using postpartum pelvimetry and antepartum fetal biometry to calculate FPI successfully identified 100% of the patients who ultimately required cesarean section for FPD, with a false positive rate of 5%. Pelvimetry performed postpartum in an index pregnancy may be used in future pregnancies, in combination with antepartum fetal ultrasound, to calculate FPI and predict the likelihood of FPD.

Adult↗